About & Team \u2014 Azuriya Pharma<\/title>\n<meta name=\"description\" content=\"Azuriya Pharma is led by seasoned biotech operators with over 100 years of combined experience in translational science, drug development, capital markets, and pharma M&A.\">\n<link rel=\"icon\" href=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\">\n<style>\n\/* ============================================================\n Azuriya Pharma \u2014 Website Design System\n Derived from the Azuriya logo: indigo \/ emerald \/ violet gradient\n ============================================================ *\/\n\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Fraunces:ital,opsz,wght@0,9..144,300..900;1,9..144,300..900&family=Manrope:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500;600&display=swap');\n\n:root {\n \/* === BRAND CORE (from logo) === *\/\n --indigo: #1C1691; \/* Primary \u2014 \"Azuriya\" wordmark *\/\n --indigo-deep: #14107A; \/* Hover \/ pressed *\/\n --ink: #0B0A4E; \/* Deep background for hero \/ footer *\/\n --emerald: #00A03C; \/* Secondary \u2014 green arc *\/\n --emerald-bright:#14BE54; \/* Hover highlight *\/\n --violet: #8B4FD8; \/* Accent \u2014 gradient start *\/\n --magenta: #C850DC; \/* Accent \u2014 gradient end *\/\n\n \/* === TINTS & SURFACES === *\/\n --cloud: #F7F8FC;\n --lavender: #F0EBFA;\n --mint: #E6F7EC;\n --white: #FFFFFF;\n\n \/* === TEXT === *\/\n --ink-body: #1A1A2E; \/* body text \u2014 indigo-tinted charcoal *\/\n --ink-muted: #555566;\n --ink-subtle: #8A8A9C;\n\n \/* === LINES === *\/\n --line: #E4E4F0;\n --line-strong: #C8C8DC;\n\n \/* === EFFECTS === *\/\n --gradient-accent: linear-gradient(90deg, var(--violet) 0%, var(--magenta) 100%);\n --gradient-brand: linear-gradient(135deg, var(--indigo) 0%, var(--violet) 100%);\n --gradient-hero: linear-gradient(135deg, #0B0A4E 0%, #1C1691 60%, #2E1E8C 100%);\n\n --shadow-sm: 0 1px 2px rgba(11,10,78,0.04), 0 1px 3px rgba(11,10,78,0.06);\n --shadow-md: 0 4px 12px rgba(11,10,78,0.06), 0 8px 24px rgba(11,10,78,0.04);\n --shadow-lg: 0 12px 32px rgba(11,10,78,0.08), 0 24px 64px rgba(11,10,78,0.06);\n\n \/* === RADII === *\/\n --r-sm: 4px;\n --r-md: 8px;\n --r-lg: 14px;\n --r-xl: 22px;\n\n \/* === TYPE SCALE === *\/\n --f-display: 'Fraunces', 'Georgia', serif;\n --f-sans: 'Manrope', -apple-system, BlinkMacSystemFont, sans-serif;\n --f-mono: 'JetBrains Mono', 'SF Mono', Menlo, monospace;\n}\n\n\/* ========== RESET ========== *\/\n*, *::before, *::after { box-sizing: border-box; }\nhtml { -webkit-text-size-adjust: 100%; scroll-behavior: smooth; }\nbody {\n margin: 0;\n font-family: var(--f-sans);\n font-size: 17px;\n line-height: 1.65;\n color: var(--ink-body);\n background: var(--white);\n font-feature-settings: 'ss01', 'cv11';\n -webkit-font-smoothing: antialiased;\n -moz-osx-font-smoothing: grayscale;\n}\n@media (min-width: 1600px) {\n body { font-size: 18px; }\n}\n@media (max-width: 640px) {\n body { font-size: 16px; line-height: 1.6; }\n}\nimg { max-width: 100%; display: block; }\na { color: var(--indigo); text-decoration: none; transition: color .15s ease; }\na:hover { color: var(--violet); }\nbutton { font-family: inherit; cursor: pointer; }\n\n\/* ========== TYPOGRAPHY ========== *\/\nh1, h2, h3, h4 {\n font-family: var(--f-display);\n font-weight: 500;\n line-height: 1.12;\n letter-spacing: -0.02em;\n color: var(--ink);\n margin: 0 0 .5em;\n font-variation-settings: 'opsz' 144;\n}\nh1 { font-size: clamp(2.6rem, 5.5vw, 5rem); line-height: 1.06; }\nh2 { font-size: clamp(2rem, 4vw, 3.2rem); line-height: 1.12; }\nh3 { font-size: clamp(1.4rem, 2.4vw, 1.75rem); font-family: var(--f-sans); font-weight: 700; letter-spacing: -0.01em; line-height: 1.25; }\nh4 { font-size: 1.15rem; font-family: var(--f-sans); font-weight: 600; letter-spacing: 0; }\n\n.eyebrow {\n font-family: var(--f-sans);\n font-size: .88rem;\n font-weight: 700;\n text-transform: uppercase;\n letter-spacing: .18em;\n color: var(--emerald);\n display: inline-flex;\n align-items: center;\n gap: .55rem;\n}\n.eyebrow::before {\n content: '';\n display: inline-block;\n width: 22px;\n height: 1px;\n background: var(--emerald);\n}\n\n.lead { font-size: clamp(1.15rem, 1.4vw, 1.4rem); line-height: 1.55; color: var(--ink-muted); max-width: 62ch; }\n.mono { font-family: var(--f-mono); font-size: .92em; letter-spacing: -.01em; }\n\n\/* Italic emphasis in serif headlines gets a violet tint *\/\nh1 em, h2 em, .serif em {\n font-style: italic;\n font-weight: 400;\n background: var(--gradient-accent);\n -webkit-background-clip: text;\n background-clip: text;\n -webkit-text-fill-color: transparent;\n}\n\n\/* ========== LAYOUT ========== *\/\n.wrap { max-width: 1320px; margin: 0 auto; padding: 0 32px; }\n.narrow { max-width: 960px; margin: 0 auto; padding: 0 32px; }\n.section { padding: clamp(4rem, 8vw, 8rem) 0; }\n.section-sm { padding: clamp(2.5rem, 5vw, 4.5rem) 0; }\n@media (max-width: 640px) {\n .wrap, .narrow { padding: 0 20px; }\n}\n\n\/* ========== NAV ========== *\/\n.nav {\n position: sticky; top: 0; z-index: 50;\n background: rgba(255,255,255,.88);\n backdrop-filter: saturate(180%) blur(12px);\n -webkit-backdrop-filter: saturate(180%) blur(12px);\n border-bottom: 1px solid var(--line);\n}\n.nav-inner {\n max-width: 1320px; margin: 0 auto;\n padding: 20px 32px;\n display: flex; align-items: center; justify-content: space-between;\n gap: 32px;\n}\n.nav-brand {\n display: flex; align-items: center; gap: 10px;\n text-decoration: none;\n}\n.nav-brand img { height: 44px; width: auto; }\n.nav-links {\n display: flex; gap: 32px; align-items: center;\n list-style: none; margin: 0; padding: 0;\n}\n.nav-links a {\n font-size: 1.02rem;\n font-weight: 500;\n color: var(--ink-body);\n position: relative;\n padding: 4px 0;\n}\n.nav-links a:hover { color: var(--indigo); }\n.nav-links a.is-active { color: var(--indigo); }\n.nav-links a.is-active::after {\n content: ''; position: absolute; left: 0; right: 0; bottom: -4px;\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n}\n.nav-cta {\n padding: 12px 22px;\n border-radius: 999px;\n background: var(--indigo);\n color: var(--white) !important;\n font-weight: 600;\n font-size: .98rem;\n transition: all .15s ease;\n}\n.nav-cta:hover { background: var(--indigo-deep); transform: translateY(-1px); }\n\n.nav-toggle { display: none; background: none; border: 0; padding: 6px; cursor: pointer; }\n.nav-toggle svg { width: 28px; height: 28px; color: var(--indigo); }\n\n\/* Mobile drawer: revealed when .nav has .is-open *\/\n.nav-mobile {\n display: none;\n border-top: 1px solid var(--line);\n background: var(--white);\n padding: 16px 32px 24px;\n}\n.nav-mobile ul { list-style: none; margin: 0; padding: 0; }\n.nav-mobile li { border-bottom: 1px solid var(--line); }\n.nav-mobile li:last-child { border-bottom: 0; }\n.nav-mobile a {\n display: block;\n padding: 16px 0;\n font-size: 1.12rem;\n font-weight: 500;\n color: var(--ink);\n}\n.nav-mobile a:hover, .nav-mobile a.is-active { color: var(--indigo); }\n.nav-mobile .nav-cta {\n display: inline-block;\n margin-top: 20px;\n color: var(--white) !important;\n}\n.nav.is-open .nav-mobile { display: block; }\n\n@media (max-width: 1024px) {\n .nav-links { display: none; }\n .nav-toggle { display: block; }\n .nav-inner > .nav-cta { display: none; } \/* Contact CTA moves into drawer *\/\n}\n@media (max-width: 640px) {\n .nav-inner { padding: 16px 20px; }\n .nav-brand img { height: 38px; }\n .nav-mobile { padding: 16px 20px 24px; }\n}\n\n\/* ========== BUTTONS ========== *\/\n.btn {\n display: inline-flex; align-items: center; gap: 8px;\n padding: 16px 28px;\n border-radius: 999px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: all .18s ease;\n border: 0;\n}\n.btn-primary { background: var(--indigo); color: var(--white); }\n.btn-primary:hover { background: var(--indigo-deep); color: var(--white); transform: translateY(-1px); box-shadow: var(--shadow-md); }\n\n.btn-emerald { background: var(--emerald); color: var(--white); }\n.btn-emerald:hover { background: var(--emerald-bright); color: var(--white); transform: translateY(-1px); }\n\n.btn-ghost {\n background: transparent;\n color: var(--indigo);\n border: 1.5px solid var(--line-strong);\n}\n.btn-ghost:hover { border-color: var(--indigo); background: var(--lavender); color: var(--indigo); }\n\n.btn-light {\n background: rgba(255,255,255,0.1);\n color: var(--white);\n border: 1.5px solid rgba(255,255,255,0.25);\n backdrop-filter: blur(8px);\n}\n.btn-light:hover { background: rgba(255,255,255,0.18); color: var(--white); border-color: rgba(255,255,255,0.5); }\n\n\/* ========== HERO ========== *\/\n.hero {\n position: relative;\n background: var(--gradient-hero);\n color: var(--white);\n padding: clamp(5rem, 10vw, 8rem) 0 clamp(4rem, 8vw, 6rem);\n overflow: hidden;\n}\n.hero::before {\n \/* subtle molecular network texture *\/\n content: '';\n position: absolute; inset: 0;\n background-image:\n radial-gradient(circle at 20% 30%, rgba(139,79,216,0.18) 0%, transparent 40%),\n radial-gradient(circle at 80% 70%, rgba(0,160,60,0.12) 0%, transparent 45%),\n radial-gradient(circle at 50% 100%, rgba(200,80,220,0.10) 0%, transparent 50%);\n pointer-events: none;\n}\n.hero::after {\n content: '';\n position: absolute; inset: 0;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' width='160' height='160' viewBox='0 0 160 160'><g fill='none' stroke='white' stroke-opacity='0.05' stroke-width='1'><circle cx='80' cy='80' r='3'\/><circle cx='20' cy='40' r='2'\/><circle cx='140' cy='120' r='2'\/><circle cx='40' cy='130' r='2.5'\/><circle cx='120' cy='30' r='2.5'\/><path d='M80 80 L20 40 M80 80 L140 120 M80 80 L40 130 M80 80 L120 30'\/><\/g><\/svg>\");\n background-size: 320px 320px;\n opacity: .5;\n pointer-events: none;\n}\n.hero > .wrap { position: relative; z-index: 1; }\n.hero h1 { color: var(--white); }\n.hero .eyebrow { color: #6FE5A1; }\n.hero .eyebrow::before { background: #6FE5A1; }\n.hero .lead { color: rgba(255,255,255,.85); font-size: clamp(1.2rem, 1.5vw, 1.45rem); max-width: 58ch; }\n\n\/* ========== CARD \/ PANEL ========== *\/\n.card {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 28px;\n transition: all .2s ease;\n}\n.card:hover { border-color: var(--line-strong); box-shadow: var(--shadow-md); transform: translateY(-2px); }\n.card-tint-lav { background: var(--lavender); border-color: transparent; }\n.card-tint-mint { background: var(--mint); border-color: transparent; }\n\n\/* ========== STAT STRIP ========== *\/\n.stats {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 0;\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n overflow: hidden;\n background: var(--white);\n}\n.stat {\n padding: 40px 32px;\n border-right: 1px solid var(--line);\n position: relative;\n}\n.stat:last-child { border-right: 0; }\n.stat-value {\n font-family: var(--f-display);\n font-size: clamp(2.4rem, 4.5vw, 3.6rem);\n font-weight: 500;\n line-height: 1;\n color: var(--indigo);\n letter-spacing: -0.03em;\n margin-bottom: 10px;\n}\n.stat-label {\n font-size: .88rem;\n text-transform: uppercase;\n letter-spacing: .12em;\n color: var(--ink-muted);\n font-weight: 600;\n}\n.stat-note { font-size: .95rem; color: var(--ink-muted); margin-top: 6px; }\n@media (max-width: 720px) {\n .stat { padding: 28px 24px; border-right: 0; border-bottom: 1px solid var(--line); }\n .stat:last-child { border-bottom: 0; }\n}\n\n\/* ========== PILLAR GRID ========== *\/\n.pillars {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 24px;\n}\n.pillar {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 32px;\n position: relative;\n transition: all .2s ease;\n}\n.pillar:hover { border-color: var(--indigo); transform: translateY(-3px); box-shadow: var(--shadow-md); }\n.pillar-num {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n margin-bottom: 12px;\n letter-spacing: .02em;\n}\n.pillar-title {\n font-family: var(--f-display);\n font-size: clamp(1.4rem, 1.8vw, 1.65rem);\n font-weight: 500;\n letter-spacing: -0.015em;\n color: var(--ink);\n margin: 0 0 14px;\n line-height: 1.15;\n}\n.pillar-body { font-size: 1rem; color: var(--ink-muted); line-height: 1.6; }\n@media (max-width: 640px) {\n .pillars { grid-template-columns: 1fr; gap: 16px; }\n .pillar { padding: 24px; }\n}\n\n\/* ========== TABLE ========== *\/\n.tbl-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 0 -4px; padding: 0 4px; }\n.tbl {\n width: 100%;\n border-collapse: collapse;\n font-size: 1rem;\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-md);\n overflow: hidden;\n}\n.tbl th {\n text-align: left;\n padding: 16px 20px;\n background: var(--cloud);\n border-bottom: 1px solid var(--line);\n font-size: .82rem;\n text-transform: uppercase;\n letter-spacing: .1em;\n color: var(--ink-muted);\n font-weight: 700;\n}\n.tbl td {\n padding: 16px 20px;\n border-bottom: 1px solid var(--line);\n vertical-align: top;\n}\n.tbl tr:last-child td { border-bottom: 0; }\n.tbl tr:hover td { background: var(--cloud); }\n@media (max-width: 640px) {\n .tbl { font-size: .95rem; min-width: 560px; }\n .tbl th, .tbl td { padding: 12px 14px; }\n}\n\n\/* ========== BADGES & CHIPS ========== *\/\n.badge {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 4px 11px;\n font-size: .78rem;\n font-weight: 700;\n letter-spacing: .08em;\n text-transform: uppercase;\n border-radius: 4px;\n}\n.badge-new { background: var(--emerald); color: var(--white); }\n.badge-indigo { background: var(--lavender); color: var(--indigo); }\n.badge-violet { background: linear-gradient(90deg, rgba(139,79,216,.15), rgba(200,80,220,.15)); color: var(--violet); }\n.badge-outline{ background: transparent; color: var(--ink-muted); border: 1px solid var(--line-strong); }\n\n.chip {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 6px 14px;\n font-size: .88rem;\n font-weight: 500;\n border-radius: 999px;\n background: var(--cloud);\n border: 1px solid var(--line);\n color: var(--ink-body);\n}\n.chip.is-active { background: var(--indigo); color: var(--white); border-color: var(--indigo); }\n.chip:hover:not(.is-active) { background: var(--lavender); border-color: var(--violet); color: var(--indigo); cursor: pointer; }\n\n\/* ========== SECTION DIVIDER ========== *\/\n.divider {\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n width: 60px;\n margin: 0 0 24px;\n}\n\n\/* ========== FOOTER ========== *\/\n.foot {\n background: var(--ink);\n color: rgba(255,255,255,.78);\n padding: 72px 0 32px;\n margin-top: 72px;\n}\n.foot a { color: rgba(255,255,255,.78); }\n.foot a:hover { color: var(--white); }\n.foot-grid {\n display: grid;\n grid-template-columns: 2fr 1fr 1fr 1fr;\n gap: 56px;\n margin-bottom: 56px;\n}\n.foot h4 {\n color: var(--white);\n font-size: .85rem;\n text-transform: uppercase;\n letter-spacing: .15em;\n margin: 0 0 18px;\n font-weight: 700;\n}\n.foot ul { list-style: none; padding: 0; margin: 0; }\n.foot ul li { margin-bottom: 12px; font-size: 1rem; }\n.foot-brand img { height: 54px; margin-bottom: 20px; filter: brightness(0) invert(1) opacity(.88); }\n.foot-copy {\n padding-top: 32px;\n border-top: 1px solid rgba(255,255,255,.12);\n font-size: .9rem;\n display: flex;\n justify-content: space-between;\n flex-wrap: wrap;\n gap: 16px;\n}\n@media (max-width: 900px) {\n .foot-grid { grid-template-columns: 1fr 1fr; gap: 36px; }\n}\n@media (max-width: 520px) {\n .foot-grid { grid-template-columns: 1fr; gap: 32px; }\n .foot { padding: 56px 0 24px; }\n}\n\n\/* ========== UTILS ========== *\/\n.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; }\n.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 28px; }\n.grid-4 { display: grid; grid-template-columns: repeat(4, 1fr); gap: 24px; }\n@media (max-width: 1024px) {\n .grid-4 { grid-template-columns: repeat(2, 1fr); }\n}\n@media (max-width: 800px) {\n .grid-2, .grid-3 { grid-template-columns: 1fr; gap: 32px; }\n}\n@media (max-width: 640px) {\n .grid-4 { grid-template-columns: 1fr; gap: 16px; }\n}\n\n.text-center { text-align: center; }\n.mt-1 { margin-top: 8px; } .mt-2 { margin-top: 16px; } .mt-3 { margin-top: 24px; } .mt-4 { margin-top: 40px; } .mt-5 { margin-top: 64px; }\n.mb-1 { margin-bottom: 8px; } .mb-2 { margin-bottom: 16px; } .mb-3 { margin-bottom: 24px; } .mb-4 { margin-bottom: 40px; }\n\n\/* Tint backgrounds for sections *\/\n.bg-cloud { background: var(--cloud); }\n.bg-lavender { background: var(--lavender); }\n.bg-mint { background: var(--mint); }\n.bg-ink { background: var(--ink); color: var(--white); }\n.bg-ink h1, .bg-ink h2, .bg-ink h3 { color: var(--white); }\n\n\/* Checkmark list *\/\n.checklist { list-style: none; padding: 0; margin: 0; }\n.checklist li {\n padding: 10px 0 10px 34px;\n position: relative;\n line-height: 1.55;\n font-size: 1rem;\n}\n.checklist li::before {\n content: '';\n position: absolute; left: 0; top: 14px;\n width: 20px; height: 20px;\n background: var(--emerald);\n border-radius: 50%;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 12 12'><path fill='none' stroke='white' stroke-width='2' stroke-linecap='round' stroke-linejoin='round' d='M2.5 6.5 L5 9 L9.5 3.5'\/><\/svg>\");\n background-size: 13px 13px;\n background-position: center;\n background-repeat: no-repeat;\n}\n\n\/* Forms *\/\n.form-row { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }\n@media (max-width: 600px) { .form-row { grid-template-columns: 1fr; gap: 16px; margin-bottom: 16px; } }\n\n.field {\n display: block;\n width: 100%;\n padding: 15px 17px;\n font-family: inherit;\n font-size: 1.02rem;\n color: var(--ink-body);\n background: var(--white);\n border: 1.5px solid var(--line-strong);\n border-radius: var(--r-md);\n transition: border-color .15s ease;\n}\n.field:focus { outline: 0; border-color: var(--indigo); box-shadow: 0 0 0 3px rgba(28,22,145,.12); }\n.label {\n display: block;\n font-size: .92rem;\n font-weight: 600;\n color: var(--ink-body);\n margin-bottom: 8px;\n letter-spacing: .01em;\n}\ntextarea.field { min-height: 160px; resize: vertical; }\n\n\/* Scientific accent \u2014 small molecule chip *\/\n.mol-chip {\n display: inline-flex; align-items: baseline; gap: 6px;\n padding: 4px 11px;\n background: var(--ink);\n color: var(--white);\n border-radius: 4px;\n font-family: var(--f-mono);\n font-size: .85rem;\n font-weight: 500;\n letter-spacing: .02em;\n}\n\n\/* Accordion \/ expandable *\/\n.timeline {\n position: relative;\n padding-left: 32px;\n}\n.timeline::before {\n content: ''; position: absolute;\n left: 7px; top: 6px; bottom: 6px;\n width: 2px;\n background: linear-gradient(180deg, var(--indigo) 0%, var(--violet) 50%, var(--magenta) 100%);\n border-radius: 2px;\n}\n.timeline-item { position: relative; padding-bottom: 32px; }\n.timeline-item::before {\n content: ''; position: absolute;\n left: -32px; top: 6px;\n width: 16px; height: 16px;\n background: var(--white);\n border: 3px solid var(--indigo);\n border-radius: 50%;\n}\n.timeline-item:last-child { padding-bottom: 0; }\n.timeline-date {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n text-transform: uppercase;\n letter-spacing: .06em;\n margin-bottom: 6px;\n}\n.timeline-title { font-weight: 700; font-size: 1.15rem; color: var(--ink); margin-bottom: 6px; }\n.timeline-body { color: var(--ink-muted); font-size: 1rem; line-height: 1.6; }\n\n\/* Legal\/disclaimer microcopy *\/\n.fine { font-size: .88rem; color: var(--ink-muted); line-height: 1.6; }\n\n\/* ========== RESPONSIVE FINE-TUNING ========== *\/\n\n\/* Tablet tuning *\/\n@media (max-width: 1024px) {\n .hero { padding: clamp(4rem, 8vw, 6rem) 0 clamp(3rem, 6vw, 5rem); }\n}\n\n\/* Mobile tuning \u2014 < 640px *\/\n@media (max-width: 640px) {\n h1 { font-size: clamp(2.1rem, 9vw, 3rem); }\n h2 { font-size: clamp(1.65rem, 6.5vw, 2.2rem); }\n h3 { font-size: 1.25rem; }\n .lead { font-size: 1.08rem; }\n .hero { padding: 3.5rem 0 3rem; }\n .hero .lead { font-size: 1.08rem; }\n .section { padding: 3.5rem 0; }\n .section-sm { padding: 2.5rem 0; }\n .card, .pillar { padding: 24px; }\n .btn { padding: 14px 22px; font-size: .95rem; }\n .stat-value { font-size: clamp(2.2rem, 10vw, 2.8rem); }\n}\n\n\/* Small mobile \u2014 < 380px *\/\n@media (max-width: 380px) {\n body { font-size: 15px; }\n h1 { font-size: 2rem; }\n .wrap, .narrow { padding: 0 16px; }\n .hero { padding: 3rem 0 2.5rem; }\n}\n\n\/* Safety: horizontal overflow prevention *\/\nhtml, body { overflow-x: hidden; max-width: 100%; }\nimg, svg, video { max-width: 100%; height: auto; }\ntable { max-width: 100%; }\n\n<\/style>\n<\/head>\n<body>\n\n<header class=\"nav\">\n <div class=\"nav-inner\">\n <a class=\"nav-brand\" href=\"index.html\"><img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\"><\/a>\n <nav><ul class=\"nav-links\">\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\" class=\"is-active\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/nav>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n\n <div class=\"nav-mobile\">\n <ul>\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\" class=\"is-active\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n<\/header>\n\n\n<section class=\"hero\" style=\"padding:clamp(4rem,7vw,6rem) 0;\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">About Azuriya<\/span>\n <h1 style=\"margin-top:22px;\">Seasoned operators.<br><em>A once-in-a-generation asset.<\/em><\/h1>\n <p class=\"lead\" style=\"margin-top:22px;\">\n Azuriya Pharma was formed to advance APX3330 \u2014 an asset that has been shepherded through\n more than $100 million of prior development across Apexian, Eisai, and Ocuphire \u2014 into\n the indication it was always best suited for: Inflammatory Bowel Disease.\n <\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap grid-2\" style=\"align-items:start;\">\n <div>\n <span class=\"eyebrow\">Our Mission<\/span>\n <h2 class=\"mt-2\">To redefine the standard of care in IBD through upstream modulation.<\/h2>\n <\/div>\n <div>\n <p class=\"lead\">\n More than half of the 7 million people living with Inflammatory Bowel Disease worldwide\n never achieve durable remission. For decades, the industry has focused on downstream\n cytokine blockade \u2014 each new generation achieving incremental improvements while leaving\n the root drivers of disease untouched.\n <\/p>\n <p class=\"lead mt-2\">\n APX3330 is the first oral therapy to act upstream of NF-\u03baB, HIF-1\u03b1, STAT3, and AP-1 \u2014\n without additive immunosuppression. Our mandate is to rapidly prove the mechanism in\n patients, establish a clean regulatory path, and deliver an oral that pharma partners\n can combine with existing classes to close the remission gap.\n <\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\" id=\"team\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Founding Team & Board<\/span>\n <h2 class=\"mt-2\">Over 100 years of combined biotech leadership.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"pillars mt-5\">\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">MS<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Mina Sooch, MBA <span style=\"font-size:.78rem; color:var(--violet); font-family:var(--f-mono); letter-spacing:.05em; vertical-align:middle;\">FOUNDER<\/span><\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">CEO \u00b7 Board<\/div>\n <p class=\"fine\">Over 30 years of leadership in biotechnology as a serial entrepreneur, investor, and CEO. Extensive experience in private and public capital raises, corporate governance, and advancing clinical-stage assets across multiple therapeutic areas.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">MK<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Mark Kelley, PhD<\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Founder & CSO \u00b7 Apexian Pharmaceuticals<\/div>\n <p class=\"fine\">Over 30 years of experience in translational science spanning oncology, ophthalmology, IBD, and drug discovery. Founder and CSO of Apexian Pharmaceuticals since 2008. Author on numerous peer-reviewed publications establishing Ref-1 as a therapeutic target.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">DO<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Daniela Oniciu, PhD<\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Drug Development & CMC<\/div>\n <p class=\"fine\">Over 25 years of experience across drug discovery and development, including CMC, nonclinical, and regulatory strategy through NDA. Inventor of Esperion's approved LDL-lowering therapy Nexletol. Working with APX3330 since 2020.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">TT<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Tim Tichenor, MBA <span style=\"font-size:.78rem; color:var(--violet); font-family:var(--f-mono); letter-spacing:.05em; vertical-align:middle;\">FOUNDER<\/span><\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Board \u00b7 Capital Markets<\/div>\n <p class=\"fine\">Over 30 years of executive leadership with a proven track record of capital raises, board leadership, and successful exits to large pharma and private equity. Prior experience includes Pfizer, Eli Lilly, Yamatake, Arlington Capital, AKKR Searchlight, and Genstar.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:640px;\">\n <span class=\"eyebrow\">Governance & Structure<\/span>\n <h2 class=\"mt-2\">A disciplined operating model built for late-stage execution.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <\/div>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card card-tint-lav\">\n <h4>Board of Directors<\/h4>\n <p class=\"fine mt-2\">Founder-led board with independent directors drawn from clinical development, pharma business development, and capital markets. Committee structure aligned to Nasdaq corporate governance standards in anticipation of a public listing pathway.<\/p>\n <\/article>\n <article class=\"card card-tint-mint\">\n <h4>Scientific Advisory<\/h4>\n <p class=\"fine mt-2\">KOL engagement across gastroenterology and translational science. Formal SAB formation underway in parallel with Phase 2a site selection and protocol design in Australia.<\/p>\n <\/article>\n <article class=\"card\" style=\"background:linear-gradient(135deg, var(--lavender) 0%, var(--mint) 100%); border:0;\">\n <h4>Operations<\/h4>\n <p class=\"fine mt-2\">Lean core team augmented by CRO and CDMO partnerships. Australian subsidiary for CTN submission and P2a execution. Full-scale P2b run in AUS + US through established site network.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Company Formation<\/span>\n <h2 class=\"mt-2\">A clean launch with a validated asset.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"mt-4\" style=\"max-width:780px;\">\n <div class=\"timeline\">\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">Pre-2020 \u2014 Apexian Pharmaceuticals<\/div>\n <div class=\"timeline-title\">APX3330 discovered and developed by Mark Kelley's lab at Indiana University<\/div>\n <div class=\"timeline-body\">Foundational Ref-1 biology and preclinical validation. Phase 1 oncology trial (NCT03375086) establishes RP2D at 600 mg\/day.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">Eisai \u00b7 Japan<\/div>\n <div class=\"timeline-title\">~100 healthy volunteers and 422 hepatitis patients dosed<\/div>\n <div class=\"timeline-body\">Largest chronic human safety dataset on APX3330. Establishes favorable hepatic and renal safety at doses up to 600 mg.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2020 \u2013 2024 \u2014 Ocuphire Pharma<\/div>\n <div class=\"timeline-title\">ZETA-1 Phase 2b completed in diabetic retinopathy<\/div>\n <div class=\"timeline-body\">24-week chronic oral dosing at 600 mg\/day in ~50 patients. Placebo-level AE profile. ~15% of DR patients reported less worsening on the severity scale vs. placebo.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2021 \u2013 2025 \u2014 Indiana University & collaborators<\/div>\n <div class=\"timeline-title\">Six peer-reviewed publications establish IBD rationale<\/div>\n <div class=\"timeline-body\">Winnie chronic, DSS acute, CHIP, and hematopoiesis datasets published in <em>Inflamm. Bowel Dis.<\/em>, <em>Biomolecules<\/em>, <em>Blood<\/em>, <em>Communications Biology<\/em>, and <em>Cancer Cell International<\/em>.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2026 \u2014 Azuriya Pharma launched<\/div>\n <div class=\"timeline-title\">Newco formation with IP consolidation and IND transfer<\/div>\n <div class=\"timeline-body\">Azuriya secures APX3330 IP portfolio, finalizes IU licensing, transfers IND with FDA, and initiates Australian CTN submission for Phase 2a.<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-ink\">\n <div class=\"wrap text-center\" style=\"max-width:720px;\">\n <h2>Interested in learning more about our team?<\/h2>\n <p class=\"lead\" style=\"color:rgba(255,255,255,.75); margin:20px auto 28px;\">\n We welcome conversations with KOLs, business development leaders, and investors evaluating the next wave of IBD innovation.\n <\/p>\n <a href=\"contact.html\" class=\"btn btn-emerald\">Get in Touch \u2192<\/a>\n <\/div>\n<\/section>\n\n<footer class=\"foot\">\n <div class=\"wrap\">\n <div class=\"foot-grid\">\n <div class=\"foot-brand\">\n <img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\">\n <p style=\"max-width:340px; font-size:.95rem; line-height:1.6;\">A late-stage, first-in-class oral small-molecule therapy targeting root causes of Inflammatory Bowel Disease through upstream modulation.<\/p>\n <\/div>\n <div><h4>Science<\/h4><ul>\n <li><a href=\"science.html\">Mechanism of Action<\/a><\/li>\n <li><a href=\"science.html#pipeline\">Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Company<\/h4><ul>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"about.html#team\">Team<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Contact<\/h4><ul>\n <li><a href=\"contact.html\">General Inquiries<\/a><\/li>\n <li><a href=\"contact.html#partnership\">Partnerships<\/a><\/li>\n <li><a href=\"contact.html#investors\">Investor Relations<\/a><\/li>\n <\/ul><\/div>\n <\/div>\n <div class=\"foot-copy\">\n <span>\u00a9 2026 Azuriya Pharma. All rights reserved.<\/span>\n <span>APX3330 is an investigational compound and has not been approved by any regulatory authority.<\/span>\n <\/div>\n <\/div>\n<\/footer>\n\n\n<script>\n(function(){\n var nav = document.querySelector('.nav');\n var toggle = document.querySelector('.nav-toggle');\n if (!nav || !toggle) return;\n toggle.addEventListener('click', function(){ nav.classList.toggle('is-open'); });\n var mobileLinks = nav.querySelectorAll('.nav-mobile a');\n mobileLinks.forEach(function(a){\n a.addEventListener('click', function(){ nav.classList.remove('is-open'); });\n });\n})();\n<\/script>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>About & Team \u2014 Azuriya Pharma Home Science & Pipeline Publications About Investors Contact Home Science & Pipeline Publications About Investors Contact About Azuriya Seasoned operators.A once-in-a-generation asset. Azuriya Pharma was formed to advance APX3330 \u2014 an asset that has been shepherded through more than $100 million of prior development across Apexian, Eisai, and Ocuphire …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-9","page","type-page","status-publish","hentry","post","without-featured-image"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/9","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9"}],"version-history":[{"count":0,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/9\/revisions"}],"wp:attachment":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

\n\t\t\t\t

\n\t\t\t\t\t\n\n\n\n\n\nAbout & Team \u2014 Azuriya Pharma<\/title>\n<meta name=\"description\" content=\"Azuriya Pharma is led by seasoned biotech operators with over 100 years of combined experience in translational science, drug development, capital markets, and pharma M&A.\">\n<link rel=\"icon\" href=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\">\n<style>\n\/* ============================================================\n Azuriya Pharma \u2014 Website Design System\n Derived from the Azuriya logo: indigo \/ emerald \/ violet gradient\n ============================================================ *\/\n\n@import url('https:\/\/fonts.googleapis.com\/css2?family=Fraunces:ital,opsz,wght@0,9..144,300..900;1,9..144,300..900&family=Manrope:wght@300;400;500;600;700;800&family=JetBrains+Mono:wght@400;500;600&display=swap');\n\n:root {\n \/* === BRAND CORE (from logo) === *\/\n --indigo: #1C1691; \/* Primary \u2014 \"Azuriya\" wordmark *\/\n --indigo-deep: #14107A; \/* Hover \/ pressed *\/\n --ink: #0B0A4E; \/* Deep background for hero \/ footer *\/\n --emerald: #00A03C; \/* Secondary \u2014 green arc *\/\n --emerald-bright:#14BE54; \/* Hover highlight *\/\n --violet: #8B4FD8; \/* Accent \u2014 gradient start *\/\n --magenta: #C850DC; \/* Accent \u2014 gradient end *\/\n\n \/* === TINTS & SURFACES === *\/\n --cloud: #F7F8FC;\n --lavender: #F0EBFA;\n --mint: #E6F7EC;\n --white: #FFFFFF;\n\n \/* === TEXT === *\/\n --ink-body: #1A1A2E; \/* body text \u2014 indigo-tinted charcoal *\/\n --ink-muted: #555566;\n --ink-subtle: #8A8A9C;\n\n \/* === LINES === *\/\n --line: #E4E4F0;\n --line-strong: #C8C8DC;\n\n \/* === EFFECTS === *\/\n --gradient-accent: linear-gradient(90deg, var(--violet) 0%, var(--magenta) 100%);\n --gradient-brand: linear-gradient(135deg, var(--indigo) 0%, var(--violet) 100%);\n --gradient-hero: linear-gradient(135deg, #0B0A4E 0%, #1C1691 60%, #2E1E8C 100%);\n\n --shadow-sm: 0 1px 2px rgba(11,10,78,0.04), 0 1px 3px rgba(11,10,78,0.06);\n --shadow-md: 0 4px 12px rgba(11,10,78,0.06), 0 8px 24px rgba(11,10,78,0.04);\n --shadow-lg: 0 12px 32px rgba(11,10,78,0.08), 0 24px 64px rgba(11,10,78,0.06);\n\n \/* === RADII === *\/\n --r-sm: 4px;\n --r-md: 8px;\n --r-lg: 14px;\n --r-xl: 22px;\n\n \/* === TYPE SCALE === *\/\n --f-display: 'Fraunces', 'Georgia', serif;\n --f-sans: 'Manrope', -apple-system, BlinkMacSystemFont, sans-serif;\n --f-mono: 'JetBrains Mono', 'SF Mono', Menlo, monospace;\n}\n\n\/* ========== RESET ========== *\/\n*, *::before, *::after { box-sizing: border-box; }\nhtml { -webkit-text-size-adjust: 100%; scroll-behavior: smooth; }\nbody {\n margin: 0;\n font-family: var(--f-sans);\n font-size: 17px;\n line-height: 1.65;\n color: var(--ink-body);\n background: var(--white);\n font-feature-settings: 'ss01', 'cv11';\n -webkit-font-smoothing: antialiased;\n -moz-osx-font-smoothing: grayscale;\n}\n@media (min-width: 1600px) {\n body { font-size: 18px; }\n}\n@media (max-width: 640px) {\n body { font-size: 16px; line-height: 1.6; }\n}\nimg { max-width: 100%; display: block; }\na { color: var(--indigo); text-decoration: none; transition: color .15s ease; }\na:hover { color: var(--violet); }\nbutton { font-family: inherit; cursor: pointer; }\n\n\/* ========== TYPOGRAPHY ========== *\/\nh1, h2, h3, h4 {\n font-family: var(--f-display);\n font-weight: 500;\n line-height: 1.12;\n letter-spacing: -0.02em;\n color: var(--ink);\n margin: 0 0 .5em;\n font-variation-settings: 'opsz' 144;\n}\nh1 { font-size: clamp(2.6rem, 5.5vw, 5rem); line-height: 1.06; }\nh2 { font-size: clamp(2rem, 4vw, 3.2rem); line-height: 1.12; }\nh3 { font-size: clamp(1.4rem, 2.4vw, 1.75rem); font-family: var(--f-sans); font-weight: 700; letter-spacing: -0.01em; line-height: 1.25; }\nh4 { font-size: 1.15rem; font-family: var(--f-sans); font-weight: 600; letter-spacing: 0; }\n\n.eyebrow {\n font-family: var(--f-sans);\n font-size: .88rem;\n font-weight: 700;\n text-transform: uppercase;\n letter-spacing: .18em;\n color: var(--emerald);\n display: inline-flex;\n align-items: center;\n gap: .55rem;\n}\n.eyebrow::before {\n content: '';\n display: inline-block;\n width: 22px;\n height: 1px;\n background: var(--emerald);\n}\n\n.lead { font-size: clamp(1.15rem, 1.4vw, 1.4rem); line-height: 1.55; color: var(--ink-muted); max-width: 62ch; }\n.mono { font-family: var(--f-mono); font-size: .92em; letter-spacing: -.01em; }\n\n\/* Italic emphasis in serif headlines gets a violet tint *\/\nh1 em, h2 em, .serif em {\n font-style: italic;\n font-weight: 400;\n background: var(--gradient-accent);\n -webkit-background-clip: text;\n background-clip: text;\n -webkit-text-fill-color: transparent;\n}\n\n\/* ========== LAYOUT ========== *\/\n.wrap { max-width: 1320px; margin: 0 auto; padding: 0 32px; }\n.narrow { max-width: 960px; margin: 0 auto; padding: 0 32px; }\n.section { padding: clamp(4rem, 8vw, 8rem) 0; }\n.section-sm { padding: clamp(2.5rem, 5vw, 4.5rem) 0; }\n@media (max-width: 640px) {\n .wrap, .narrow { padding: 0 20px; }\n}\n\n\/* ========== NAV ========== *\/\n.nav {\n position: sticky; top: 0; z-index: 50;\n background: rgba(255,255,255,.88);\n backdrop-filter: saturate(180%) blur(12px);\n -webkit-backdrop-filter: saturate(180%) blur(12px);\n border-bottom: 1px solid var(--line);\n}\n.nav-inner {\n max-width: 1320px; margin: 0 auto;\n padding: 20px 32px;\n display: flex; align-items: center; justify-content: space-between;\n gap: 32px;\n}\n.nav-brand {\n display: flex; align-items: center; gap: 10px;\n text-decoration: none;\n}\n.nav-brand img { height: 44px; width: auto; }\n.nav-links {\n display: flex; gap: 32px; align-items: center;\n list-style: none; margin: 0; padding: 0;\n}\n.nav-links a {\n font-size: 1.02rem;\n font-weight: 500;\n color: var(--ink-body);\n position: relative;\n padding: 4px 0;\n}\n.nav-links a:hover { color: var(--indigo); }\n.nav-links a.is-active { color: var(--indigo); }\n.nav-links a.is-active::after {\n content: ''; position: absolute; left: 0; right: 0; bottom: -4px;\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n}\n.nav-cta {\n padding: 12px 22px;\n border-radius: 999px;\n background: var(--indigo);\n color: var(--white) !important;\n font-weight: 600;\n font-size: .98rem;\n transition: all .15s ease;\n}\n.nav-cta:hover { background: var(--indigo-deep); transform: translateY(-1px); }\n\n.nav-toggle { display: none; background: none; border: 0; padding: 6px; cursor: pointer; }\n.nav-toggle svg { width: 28px; height: 28px; color: var(--indigo); }\n\n\/* Mobile drawer: revealed when .nav has .is-open *\/\n.nav-mobile {\n display: none;\n border-top: 1px solid var(--line);\n background: var(--white);\n padding: 16px 32px 24px;\n}\n.nav-mobile ul { list-style: none; margin: 0; padding: 0; }\n.nav-mobile li { border-bottom: 1px solid var(--line); }\n.nav-mobile li:last-child { border-bottom: 0; }\n.nav-mobile a {\n display: block;\n padding: 16px 0;\n font-size: 1.12rem;\n font-weight: 500;\n color: var(--ink);\n}\n.nav-mobile a:hover, .nav-mobile a.is-active { color: var(--indigo); }\n.nav-mobile .nav-cta {\n display: inline-block;\n margin-top: 20px;\n color: var(--white) !important;\n}\n.nav.is-open .nav-mobile { display: block; }\n\n@media (max-width: 1024px) {\n .nav-links { display: none; }\n .nav-toggle { display: block; }\n .nav-inner > .nav-cta { display: none; } \/* Contact CTA moves into drawer *\/\n}\n@media (max-width: 640px) {\n .nav-inner { padding: 16px 20px; }\n .nav-brand img { height: 38px; }\n .nav-mobile { padding: 16px 20px 24px; }\n}\n\n\/* ========== BUTTONS ========== *\/\n.btn {\n display: inline-flex; align-items: center; gap: 8px;\n padding: 16px 28px;\n border-radius: 999px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: all .18s ease;\n border: 0;\n}\n.btn-primary { background: var(--indigo); color: var(--white); }\n.btn-primary:hover { background: var(--indigo-deep); color: var(--white); transform: translateY(-1px); box-shadow: var(--shadow-md); }\n\n.btn-emerald { background: var(--emerald); color: var(--white); }\n.btn-emerald:hover { background: var(--emerald-bright); color: var(--white); transform: translateY(-1px); }\n\n.btn-ghost {\n background: transparent;\n color: var(--indigo);\n border: 1.5px solid var(--line-strong);\n}\n.btn-ghost:hover { border-color: var(--indigo); background: var(--lavender); color: var(--indigo); }\n\n.btn-light {\n background: rgba(255,255,255,0.1);\n color: var(--white);\n border: 1.5px solid rgba(255,255,255,0.25);\n backdrop-filter: blur(8px);\n}\n.btn-light:hover { background: rgba(255,255,255,0.18); color: var(--white); border-color: rgba(255,255,255,0.5); }\n\n\/* ========== HERO ========== *\/\n.hero {\n position: relative;\n background: var(--gradient-hero);\n color: var(--white);\n padding: clamp(5rem, 10vw, 8rem) 0 clamp(4rem, 8vw, 6rem);\n overflow: hidden;\n}\n.hero::before {\n \/* subtle molecular network texture *\/\n content: '';\n position: absolute; inset: 0;\n background-image:\n radial-gradient(circle at 20% 30%, rgba(139,79,216,0.18) 0%, transparent 40%),\n radial-gradient(circle at 80% 70%, rgba(0,160,60,0.12) 0%, transparent 45%),\n radial-gradient(circle at 50% 100%, rgba(200,80,220,0.10) 0%, transparent 50%);\n pointer-events: none;\n}\n.hero::after {\n content: '';\n position: absolute; inset: 0;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' width='160' height='160' viewBox='0 0 160 160'><g fill='none' stroke='white' stroke-opacity='0.05' stroke-width='1'><circle cx='80' cy='80' r='3'\/><circle cx='20' cy='40' r='2'\/><circle cx='140' cy='120' r='2'\/><circle cx='40' cy='130' r='2.5'\/><circle cx='120' cy='30' r='2.5'\/><path d='M80 80 L20 40 M80 80 L140 120 M80 80 L40 130 M80 80 L120 30'\/><\/g><\/svg>\");\n background-size: 320px 320px;\n opacity: .5;\n pointer-events: none;\n}\n.hero > .wrap { position: relative; z-index: 1; }\n.hero h1 { color: var(--white); }\n.hero .eyebrow { color: #6FE5A1; }\n.hero .eyebrow::before { background: #6FE5A1; }\n.hero .lead { color: rgba(255,255,255,.85); font-size: clamp(1.2rem, 1.5vw, 1.45rem); max-width: 58ch; }\n\n\/* ========== CARD \/ PANEL ========== *\/\n.card {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 28px;\n transition: all .2s ease;\n}\n.card:hover { border-color: var(--line-strong); box-shadow: var(--shadow-md); transform: translateY(-2px); }\n.card-tint-lav { background: var(--lavender); border-color: transparent; }\n.card-tint-mint { background: var(--mint); border-color: transparent; }\n\n\/* ========== STAT STRIP ========== *\/\n.stats {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 0;\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n overflow: hidden;\n background: var(--white);\n}\n.stat {\n padding: 40px 32px;\n border-right: 1px solid var(--line);\n position: relative;\n}\n.stat:last-child { border-right: 0; }\n.stat-value {\n font-family: var(--f-display);\n font-size: clamp(2.4rem, 4.5vw, 3.6rem);\n font-weight: 500;\n line-height: 1;\n color: var(--indigo);\n letter-spacing: -0.03em;\n margin-bottom: 10px;\n}\n.stat-label {\n font-size: .88rem;\n text-transform: uppercase;\n letter-spacing: .12em;\n color: var(--ink-muted);\n font-weight: 600;\n}\n.stat-note { font-size: .95rem; color: var(--ink-muted); margin-top: 6px; }\n@media (max-width: 720px) {\n .stat { padding: 28px 24px; border-right: 0; border-bottom: 1px solid var(--line); }\n .stat:last-child { border-bottom: 0; }\n}\n\n\/* ========== PILLAR GRID ========== *\/\n.pillars {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 24px;\n}\n.pillar {\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-lg);\n padding: 32px;\n position: relative;\n transition: all .2s ease;\n}\n.pillar:hover { border-color: var(--indigo); transform: translateY(-3px); box-shadow: var(--shadow-md); }\n.pillar-num {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n margin-bottom: 12px;\n letter-spacing: .02em;\n}\n.pillar-title {\n font-family: var(--f-display);\n font-size: clamp(1.4rem, 1.8vw, 1.65rem);\n font-weight: 500;\n letter-spacing: -0.015em;\n color: var(--ink);\n margin: 0 0 14px;\n line-height: 1.15;\n}\n.pillar-body { font-size: 1rem; color: var(--ink-muted); line-height: 1.6; }\n@media (max-width: 640px) {\n .pillars { grid-template-columns: 1fr; gap: 16px; }\n .pillar { padding: 24px; }\n}\n\n\/* ========== TABLE ========== *\/\n.tbl-wrap { overflow-x: auto; -webkit-overflow-scrolling: touch; margin: 0 -4px; padding: 0 4px; }\n.tbl {\n width: 100%;\n border-collapse: collapse;\n font-size: 1rem;\n background: var(--white);\n border: 1px solid var(--line);\n border-radius: var(--r-md);\n overflow: hidden;\n}\n.tbl th {\n text-align: left;\n padding: 16px 20px;\n background: var(--cloud);\n border-bottom: 1px solid var(--line);\n font-size: .82rem;\n text-transform: uppercase;\n letter-spacing: .1em;\n color: var(--ink-muted);\n font-weight: 700;\n}\n.tbl td {\n padding: 16px 20px;\n border-bottom: 1px solid var(--line);\n vertical-align: top;\n}\n.tbl tr:last-child td { border-bottom: 0; }\n.tbl tr:hover td { background: var(--cloud); }\n@media (max-width: 640px) {\n .tbl { font-size: .95rem; min-width: 560px; }\n .tbl th, .tbl td { padding: 12px 14px; }\n}\n\n\/* ========== BADGES & CHIPS ========== *\/\n.badge {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 4px 11px;\n font-size: .78rem;\n font-weight: 700;\n letter-spacing: .08em;\n text-transform: uppercase;\n border-radius: 4px;\n}\n.badge-new { background: var(--emerald); color: var(--white); }\n.badge-indigo { background: var(--lavender); color: var(--indigo); }\n.badge-violet { background: linear-gradient(90deg, rgba(139,79,216,.15), rgba(200,80,220,.15)); color: var(--violet); }\n.badge-outline{ background: transparent; color: var(--ink-muted); border: 1px solid var(--line-strong); }\n\n.chip {\n display: inline-flex; align-items: center; gap: 5px;\n padding: 6px 14px;\n font-size: .88rem;\n font-weight: 500;\n border-radius: 999px;\n background: var(--cloud);\n border: 1px solid var(--line);\n color: var(--ink-body);\n}\n.chip.is-active { background: var(--indigo); color: var(--white); border-color: var(--indigo); }\n.chip:hover:not(.is-active) { background: var(--lavender); border-color: var(--violet); color: var(--indigo); cursor: pointer; }\n\n\/* ========== SECTION DIVIDER ========== *\/\n.divider {\n height: 2px;\n background: var(--gradient-accent);\n border-radius: 2px;\n width: 60px;\n margin: 0 0 24px;\n}\n\n\/* ========== FOOTER ========== *\/\n.foot {\n background: var(--ink);\n color: rgba(255,255,255,.78);\n padding: 72px 0 32px;\n margin-top: 72px;\n}\n.foot a { color: rgba(255,255,255,.78); }\n.foot a:hover { color: var(--white); }\n.foot-grid {\n display: grid;\n grid-template-columns: 2fr 1fr 1fr 1fr;\n gap: 56px;\n margin-bottom: 56px;\n}\n.foot h4 {\n color: var(--white);\n font-size: .85rem;\n text-transform: uppercase;\n letter-spacing: .15em;\n margin: 0 0 18px;\n font-weight: 700;\n}\n.foot ul { list-style: none; padding: 0; margin: 0; }\n.foot ul li { margin-bottom: 12px; font-size: 1rem; }\n.foot-brand img { height: 54px; margin-bottom: 20px; filter: brightness(0) invert(1) opacity(.88); }\n.foot-copy {\n padding-top: 32px;\n border-top: 1px solid rgba(255,255,255,.12);\n font-size: .9rem;\n display: flex;\n justify-content: space-between;\n flex-wrap: wrap;\n gap: 16px;\n}\n@media (max-width: 900px) {\n .foot-grid { grid-template-columns: 1fr 1fr; gap: 36px; }\n}\n@media (max-width: 520px) {\n .foot-grid { grid-template-columns: 1fr; gap: 32px; }\n .foot { padding: 56px 0 24px; }\n}\n\n\/* ========== UTILS ========== *\/\n.grid-2 { display: grid; grid-template-columns: 1fr 1fr; gap: 56px; }\n.grid-3 { display: grid; grid-template-columns: repeat(3, 1fr); gap: 28px; }\n.grid-4 { display: grid; grid-template-columns: repeat(4, 1fr); gap: 24px; }\n@media (max-width: 1024px) {\n .grid-4 { grid-template-columns: repeat(2, 1fr); }\n}\n@media (max-width: 800px) {\n .grid-2, .grid-3 { grid-template-columns: 1fr; gap: 32px; }\n}\n@media (max-width: 640px) {\n .grid-4 { grid-template-columns: 1fr; gap: 16px; }\n}\n\n.text-center { text-align: center; }\n.mt-1 { margin-top: 8px; } .mt-2 { margin-top: 16px; } .mt-3 { margin-top: 24px; } .mt-4 { margin-top: 40px; } .mt-5 { margin-top: 64px; }\n.mb-1 { margin-bottom: 8px; } .mb-2 { margin-bottom: 16px; } .mb-3 { margin-bottom: 24px; } .mb-4 { margin-bottom: 40px; }\n\n\/* Tint backgrounds for sections *\/\n.bg-cloud { background: var(--cloud); }\n.bg-lavender { background: var(--lavender); }\n.bg-mint { background: var(--mint); }\n.bg-ink { background: var(--ink); color: var(--white); }\n.bg-ink h1, .bg-ink h2, .bg-ink h3 { color: var(--white); }\n\n\/* Checkmark list *\/\n.checklist { list-style: none; padding: 0; margin: 0; }\n.checklist li {\n padding: 10px 0 10px 34px;\n position: relative;\n line-height: 1.55;\n font-size: 1rem;\n}\n.checklist li::before {\n content: '';\n position: absolute; left: 0; top: 14px;\n width: 20px; height: 20px;\n background: var(--emerald);\n border-radius: 50%;\n background-image: url(\"data:image\/svg+xml;utf8,<svg xmlns='http:\/\/www.w3.org\/2000\/svg' viewBox='0 0 12 12'><path fill='none' stroke='white' stroke-width='2' stroke-linecap='round' stroke-linejoin='round' d='M2.5 6.5 L5 9 L9.5 3.5'\/><\/svg>\");\n background-size: 13px 13px;\n background-position: center;\n background-repeat: no-repeat;\n}\n\n\/* Forms *\/\n.form-row { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 20px; }\n@media (max-width: 600px) { .form-row { grid-template-columns: 1fr; gap: 16px; margin-bottom: 16px; } }\n\n.field {\n display: block;\n width: 100%;\n padding: 15px 17px;\n font-family: inherit;\n font-size: 1.02rem;\n color: var(--ink-body);\n background: var(--white);\n border: 1.5px solid var(--line-strong);\n border-radius: var(--r-md);\n transition: border-color .15s ease;\n}\n.field:focus { outline: 0; border-color: var(--indigo); box-shadow: 0 0 0 3px rgba(28,22,145,.12); }\n.label {\n display: block;\n font-size: .92rem;\n font-weight: 600;\n color: var(--ink-body);\n margin-bottom: 8px;\n letter-spacing: .01em;\n}\ntextarea.field { min-height: 160px; resize: vertical; }\n\n\/* Scientific accent \u2014 small molecule chip *\/\n.mol-chip {\n display: inline-flex; align-items: baseline; gap: 6px;\n padding: 4px 11px;\n background: var(--ink);\n color: var(--white);\n border-radius: 4px;\n font-family: var(--f-mono);\n font-size: .85rem;\n font-weight: 500;\n letter-spacing: .02em;\n}\n\n\/* Accordion \/ expandable *\/\n.timeline {\n position: relative;\n padding-left: 32px;\n}\n.timeline::before {\n content: ''; position: absolute;\n left: 7px; top: 6px; bottom: 6px;\n width: 2px;\n background: linear-gradient(180deg, var(--indigo) 0%, var(--violet) 50%, var(--magenta) 100%);\n border-radius: 2px;\n}\n.timeline-item { position: relative; padding-bottom: 32px; }\n.timeline-item::before {\n content: ''; position: absolute;\n left: -32px; top: 6px;\n width: 16px; height: 16px;\n background: var(--white);\n border: 3px solid var(--indigo);\n border-radius: 50%;\n}\n.timeline-item:last-child { padding-bottom: 0; }\n.timeline-date {\n font-family: var(--f-mono);\n font-size: .88rem;\n color: var(--violet);\n font-weight: 600;\n text-transform: uppercase;\n letter-spacing: .06em;\n margin-bottom: 6px;\n}\n.timeline-title { font-weight: 700; font-size: 1.15rem; color: var(--ink); margin-bottom: 6px; }\n.timeline-body { color: var(--ink-muted); font-size: 1rem; line-height: 1.6; }\n\n\/* Legal\/disclaimer microcopy *\/\n.fine { font-size: .88rem; color: var(--ink-muted); line-height: 1.6; }\n\n\/* ========== RESPONSIVE FINE-TUNING ========== *\/\n\n\/* Tablet tuning *\/\n@media (max-width: 1024px) {\n .hero { padding: clamp(4rem, 8vw, 6rem) 0 clamp(3rem, 6vw, 5rem); }\n}\n\n\/* Mobile tuning \u2014 < 640px *\/\n@media (max-width: 640px) {\n h1 { font-size: clamp(2.1rem, 9vw, 3rem); }\n h2 { font-size: clamp(1.65rem, 6.5vw, 2.2rem); }\n h3 { font-size: 1.25rem; }\n .lead { font-size: 1.08rem; }\n .hero { padding: 3.5rem 0 3rem; }\n .hero .lead { font-size: 1.08rem; }\n .section { padding: 3.5rem 0; }\n .section-sm { padding: 2.5rem 0; }\n .card, .pillar { padding: 24px; }\n .btn { padding: 14px 22px; font-size: .95rem; }\n .stat-value { font-size: clamp(2.2rem, 10vw, 2.8rem); }\n}\n\n\/* Small mobile \u2014 < 380px *\/\n@media (max-width: 380px) {\n body { font-size: 15px; }\n h1 { font-size: 2rem; }\n .wrap, .narrow { padding: 0 16px; }\n .hero { padding: 3rem 0 2.5rem; }\n}\n\n\/* Safety: horizontal overflow prevention *\/\nhtml, body { overflow-x: hidden; max-width: 100%; }\nimg, svg, video { max-width: 100%; height: auto; }\ntable { max-width: 100%; }\n\n<\/style>\n<\/head>\n<body>\n\n<header class=\"nav\">\n <div class=\"nav-inner\">\n <a class=\"nav-brand\" href=\"index.html\"><img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\"><\/a>\n <nav><ul class=\"nav-links\">\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\" class=\"is-active\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/nav>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n\n <div class=\"nav-mobile\">\n <ul>\n <li><a href=\"index.html\">Home<\/a><\/li>\n <li><a href=\"science.html\">Science & Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <li><a href=\"about.html\" class=\"is-active\">About<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul>\n <a class=\"nav-cta\" href=\"contact.html\">Contact<\/a>\n <\/div>\n<\/header>\n\n\n<section class=\"hero\" style=\"padding:clamp(4rem,7vw,6rem) 0;\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">About Azuriya<\/span>\n <h1 style=\"margin-top:22px;\">Seasoned operators.<br><em>A once-in-a-generation asset.<\/em><\/h1>\n <p class=\"lead\" style=\"margin-top:22px;\">\n Azuriya Pharma was formed to advance APX3330 \u2014 an asset that has been shepherded through\n more than $100 million of prior development across Apexian, Eisai, and Ocuphire \u2014 into\n the indication it was always best suited for: Inflammatory Bowel Disease.\n <\/p>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap grid-2\" style=\"align-items:start;\">\n <div>\n <span class=\"eyebrow\">Our Mission<\/span>\n <h2 class=\"mt-2\">To redefine the standard of care in IBD through upstream modulation.<\/h2>\n <\/div>\n <div>\n <p class=\"lead\">\n More than half of the 7 million people living with Inflammatory Bowel Disease worldwide\n never achieve durable remission. For decades, the industry has focused on downstream\n cytokine blockade \u2014 each new generation achieving incremental improvements while leaving\n the root drivers of disease untouched.\n <\/p>\n <p class=\"lead mt-2\">\n APX3330 is the first oral therapy to act upstream of NF-\u03baB, HIF-1\u03b1, STAT3, and AP-1 \u2014\n without additive immunosuppression. Our mandate is to rapidly prove the mechanism in\n patients, establish a clean regulatory path, and deliver an oral that pharma partners\n can combine with existing classes to close the remission gap.\n <\/p>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\" id=\"team\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Founding Team & Board<\/span>\n <h2 class=\"mt-2\">Over 100 years of combined biotech leadership.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"pillars mt-5\">\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">MS<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Mina Sooch, MBA <span style=\"font-size:.78rem; color:var(--violet); font-family:var(--f-mono); letter-spacing:.05em; vertical-align:middle;\">FOUNDER<\/span><\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">CEO \u00b7 Board<\/div>\n <p class=\"fine\">Over 30 years of leadership in biotechnology as a serial entrepreneur, investor, and CEO. Extensive experience in private and public capital raises, corporate governance, and advancing clinical-stage assets across multiple therapeutic areas.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">MK<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Mark Kelley, PhD<\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Founder & CSO \u00b7 Apexian Pharmaceuticals<\/div>\n <p class=\"fine\">Over 30 years of experience in translational science spanning oncology, ophthalmology, IBD, and drug discovery. Founder and CSO of Apexian Pharmaceuticals since 2008. Author on numerous peer-reviewed publications establishing Ref-1 as a therapeutic target.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">DO<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Daniela Oniciu, PhD<\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Drug Development & CMC<\/div>\n <p class=\"fine\">Over 25 years of experience across drug discovery and development, including CMC, nonclinical, and regulatory strategy through NDA. Inventor of Esperion's approved LDL-lowering therapy Nexletol. Working with APX3330 since 2020.<\/p>\n <\/article>\n\n \n <article class=\"card\" style=\"background:var(--white);\">\n <div style=\"width:88px; height:88px; border-radius:50%; background:var(--gradient-brand); display:flex; align-items:center; justify-content:center; color:var(--white); font-family:var(--f-display); font-size:1.9rem; font-weight:500; margin-bottom:20px; letter-spacing:-0.02em;\">TT<\/div>\n <h3 style=\"font-family:var(--f-display); font-weight:500; font-size:1.5rem; letter-spacing:-0.02em;\">Tim Tichenor, MBA <span style=\"font-size:.78rem; color:var(--violet); font-family:var(--f-mono); letter-spacing:.05em; vertical-align:middle;\">FOUNDER<\/span><\/h3>\n <div class=\"mono\" style=\"font-size:.85rem; color:var(--indigo); margin-bottom:14px;\">Board \u00b7 Capital Markets<\/div>\n <p class=\"fine\">Over 30 years of executive leadership with a proven track record of capital raises, board leadership, and successful exits to large pharma and private equity. Prior experience includes Pfizer, Eli Lilly, Yamatake, Arlington Capital, AKKR Searchlight, and Genstar.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section\">\n <div class=\"wrap\">\n <div style=\"max-width:640px;\">\n <span class=\"eyebrow\">Governance & Structure<\/span>\n <h2 class=\"mt-2\">A disciplined operating model built for late-stage execution.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n <\/div>\n\n <div class=\"grid-3 mt-4\">\n <article class=\"card card-tint-lav\">\n <h4>Board of Directors<\/h4>\n <p class=\"fine mt-2\">Founder-led board with independent directors drawn from clinical development, pharma business development, and capital markets. Committee structure aligned to Nasdaq corporate governance standards in anticipation of a public listing pathway.<\/p>\n <\/article>\n <article class=\"card card-tint-mint\">\n <h4>Scientific Advisory<\/h4>\n <p class=\"fine mt-2\">KOL engagement across gastroenterology and translational science. Formal SAB formation underway in parallel with Phase 2a site selection and protocol design in Australia.<\/p>\n <\/article>\n <article class=\"card\" style=\"background:linear-gradient(135deg, var(--lavender) 0%, var(--mint) 100%); border:0;\">\n <h4>Operations<\/h4>\n <p class=\"fine mt-2\">Lean core team augmented by CRO and CDMO partnerships. Australian subsidiary for CTN submission and P2a execution. Full-scale P2b run in AUS + US through established site network.<\/p>\n <\/article>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-cloud\">\n <div class=\"wrap\">\n <span class=\"eyebrow\">Company Formation<\/span>\n <h2 class=\"mt-2\">A clean launch with a validated asset.<\/h2>\n <div class=\"divider mt-3\"><\/div>\n\n <div class=\"mt-4\" style=\"max-width:780px;\">\n <div class=\"timeline\">\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">Pre-2020 \u2014 Apexian Pharmaceuticals<\/div>\n <div class=\"timeline-title\">APX3330 discovered and developed by Mark Kelley's lab at Indiana University<\/div>\n <div class=\"timeline-body\">Foundational Ref-1 biology and preclinical validation. Phase 1 oncology trial (NCT03375086) establishes RP2D at 600 mg\/day.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">Eisai \u00b7 Japan<\/div>\n <div class=\"timeline-title\">~100 healthy volunteers and 422 hepatitis patients dosed<\/div>\n <div class=\"timeline-body\">Largest chronic human safety dataset on APX3330. Establishes favorable hepatic and renal safety at doses up to 600 mg.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2020 \u2013 2024 \u2014 Ocuphire Pharma<\/div>\n <div class=\"timeline-title\">ZETA-1 Phase 2b completed in diabetic retinopathy<\/div>\n <div class=\"timeline-body\">24-week chronic oral dosing at 600 mg\/day in ~50 patients. Placebo-level AE profile. ~15% of DR patients reported less worsening on the severity scale vs. placebo.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">2021 \u2013 2025 \u2014 Indiana University & collaborators<\/div>\n <div class=\"timeline-title\">Six peer-reviewed publications establish IBD rationale<\/div>\n <div class=\"timeline-body\">Winnie chronic, DSS acute, CHIP, and hematopoiesis datasets published in <em>Inflamm. Bowel Dis.<\/em>, <em>Biomolecules<\/em>, <em>Blood<\/em>, <em>Communications Biology<\/em>, and <em>Cancer Cell International<\/em>.<\/div>\n <\/div>\n <div class=\"timeline-item\">\n <div class=\"timeline-date\">1H 2026 \u2014 Azuriya Pharma launched<\/div>\n <div class=\"timeline-title\">Newco formation with IP consolidation and IND transfer<\/div>\n <div class=\"timeline-body\">Azuriya secures APX3330 IP portfolio, finalizes IU licensing, transfers IND with FDA, and initiates Australian CTN submission for Phase 2a.<\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/section>\n\n\n<section class=\"section bg-ink\">\n <div class=\"wrap text-center\" style=\"max-width:720px;\">\n <h2>Interested in learning more about our team?<\/h2>\n <p class=\"lead\" style=\"color:rgba(255,255,255,.75); margin:20px auto 28px;\">\n We welcome conversations with KOLs, business development leaders, and investors evaluating the next wave of IBD innovation.\n <\/p>\n <a href=\"contact.html\" class=\"btn btn-emerald\">Get in Touch \u2192<\/a>\n <\/div>\n<\/section>\n\n<footer class=\"foot\">\n <div class=\"wrap\">\n <div class=\"foot-grid\">\n <div class=\"foot-brand\">\n <img decoding=\"async\" src=\"https:\/\/azuriyapharma.co\/wp-content\/uploads\/2026\/04\/Azuryia-Logo-No-Background-e1776863837551.png\" alt=\"Azuriya Pharma\">\n <p style=\"max-width:340px; font-size:.95rem; line-height:1.6;\">A late-stage, first-in-class oral small-molecule therapy targeting root causes of Inflammatory Bowel Disease through upstream modulation.<\/p>\n <\/div>\n <div><h4>Science<\/h4><ul>\n <li><a href=\"science.html\">Mechanism of Action<\/a><\/li>\n <li><a href=\"science.html#pipeline\">Pipeline<\/a><\/li>\n <li><a href=\"publications.html\">Publications<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Company<\/h4><ul>\n <li><a href=\"about.html\">About<\/a><\/li>\n <li><a href=\"about.html#team\">Team<\/a><\/li>\n <li><a href=\"investors.html\">Investors<\/a><\/li>\n <\/ul><\/div>\n <div><h4>Contact<\/h4><ul>\n <li><a href=\"contact.html\">General Inquiries<\/a><\/li>\n <li><a href=\"contact.html#partnership\">Partnerships<\/a><\/li>\n <li><a href=\"contact.html#investors\">Investor Relations<\/a><\/li>\n <\/ul><\/div>\n <\/div>\n <div class=\"foot-copy\">\n <span>\u00a9 2026 Azuriya Pharma. All rights reserved.<\/span>\n <span>APX3330 is an investigational compound and has not been approved by any regulatory authority.<\/span>\n <\/div>\n <\/div>\n<\/footer>\n\n\n<script>\n(function(){\n var nav = document.querySelector('.nav');\n var toggle = document.querySelector('.nav-toggle');\n if (!nav || !toggle) return;\n toggle.addEventListener('click', function(){ nav.classList.toggle('is-open'); });\n var mobileLinks = nav.querySelectorAll('.nav-mobile a');\n mobileLinks.forEach(function(a){\n a.addEventListener('click', function(){ nav.classList.remove('is-open'); });\n });\n})();\n<\/script>\n\n<\/body>\n<\/html>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>About & Team \u2014 Azuriya Pharma Home Science & Pipeline Publications About Investors Contact Home Science & Pipeline Publications About Investors Contact About Azuriya Seasoned operators.A once-in-a-generation asset. Azuriya Pharma was formed to advance APX3330 \u2014 an asset that has been shepherded through more than $100 million of prior development across Apexian, Eisai, and Ocuphire …<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_genesis_block_theme_hide_title":false,"footnotes":""},"class_list":["post-9","page","type-page","status-publish","hentry","post","without-featured-image"],"featured_image_src":null,"featured_image_src_square":null,"_links":{"self":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/9","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9"}],"version-history":[{"count":0,"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=\/wp\/v2\/pages\/9\/revisions"}],"wp:attachment":[{"href":"https:\/\/azuriyapharma.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}